CTLA4 and melanoma: ICIs have demonstrated significant efficacy in non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), melanoma, and triple-negative breast cancer (TNBC) by targeting checkpoint proteins such as PD-1, PD-L1, and CTLA-4.